Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 17Triple Negative Breast Neoplasms 13Ovarian Neoplasms 2Breast Cancer Metastatic 2Uterine Cervical Neoplasms 1Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer 1Stomach Neoplasms 1Neoplasms 1HR+/HER2-breast Cancer 1HER2-negative Breast Cancer Brain Metastases 1Fludzoparib" and Anti-angiogenic 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Organoids 1Advanced Triple-Negative Breast Cancer 1Advanced Triple Negative Breast Cancer 1Advanced Breast Cancer 1

Interventions

apatinib 1Vinorelbine 1Injections 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Triple-Negative Breast Cancer × apatinib × Breast × Clear all
NCT03254654 2022-04-20

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Fudan University

Phase 2 Completed
66 enrolled
Breast

Advanced Triple-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡